Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Serum Metabolites Associated with Traumatic Brain Injury Severity

By LabMedica International staff writers
Posted on 11 Oct 2016
Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults and is an example of a medical condition where there are still major deficits in diagnostics and outcome prediction.

Since the blood-brain barrier prevents diffusion of most water-soluble molecules with molecular mass over 500 dalton (Da), it hs been hypothesized that circulating small molecules or metabolites are a potential source of TBI biomarkers.

Biotechnologists from the University of Turku (Finland) and their colleagues prospectively recruited total of 389 adult patients with acute TBI and 81 patients with acute orthopedic trauma without acute or previous brain disorders, who served as controls and another 211 patients with acute TBI and 55 orthopedic trauma patients who had eligible serum samples available from a hospital in the UK. More...
Blood samples of 2 mL for metabolomic analysis were collected within 12 hours after hospital admission.

Two-Dimensional Gas Chromatography with Time-of-Flight Mass Spectrometer (GC × GC–TOFMS) analyses were carried out on an Agilent 6890 gas chromatograph equipped with a split/splitless injector (Agilent Technologies, Santa Clara, CA, USA), cryogenic dual-stage modulator and time-of-flight mass spectrometer (Leco Corporation, St. Joseph, MI, USA).

The scientists discovered that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also detected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from TBI patients at the time of hospitalization, an algorithm was developed that accurately predicted the patient outcomes (area under the curve (AUC) = 0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH), comprising clinical and computed tomography data, significantly improved prediction of patient outcomes.

The authors concluded that TBI is associated with a specific metabolic profile, which is exacerbated proportionally to the severity of TBI. High degree of concentration changes of TBI metabolites in serum as well as their proportional enrichment in brain microdialysate (BMD) is indicative of multiple underlying mechanisms including potential disruption in the blood brain barrier as well as protective response and altered metabolism due to head trauma. These findings also suggest that these metabolites may exhibit diagnostic potential in the full spectrum of TBI. The study was published originally online on July 15, 2016, as is now an article in press in the journal EbioMedicine.

Related Links:
University of Turku
Agilent Technologies
Leco

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.